GENMAB AS SP.ADR/1/10DK 1 (GE91) - Total Liabilities
Based on the latest financial reports, GENMAB AS SP.ADR/1/10DK 1 (GE91) has total liabilities worth €7.03 Billion EUR (≈ $8.21 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of GENMAB AS SP.ADR/1/10DK 1 to see how much of total assets are deployed in long-term investments.
GENMAB AS SP.ADR/1/10DK 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GENMAB AS SP.ADR/1/10DK 1 balance sheet assets.
GENMAB AS SP.ADR/1/10DK 1 Competitors by Total Liabilities
The table below lists competitors of GENMAB AS SP.ADR/1/10DK 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nippon Sanso Holdings Corp.
NYSE:NPXYY
|
USA | $1.51 Trillion |
|
Lattice Semiconductor Corporation
NASDAQ:LSCC
|
USA | $188.65 Million |
|
Chocoladefabriken Lindt & Spruengli AG N
SW:LISN
|
Switzerland | CHF4.33 Billion |
|
Tech Mahindra Limited
NSE:TECHM
|
India | Rs-300.77 Billion |
|
Corebridge Financial Inc.
NYSE:CRBG
|
USA | $404.42 Billion |
|
Bosch Limited
NSE:BOSCHLTD
|
India | Rs63.06 Billion |
|
Pinnacle Financial Partners, Inc.
NYSE:PNFP
|
USA | $114.23 Billion |
|
YPF Sociedad Anonima
NYSE:YPF
|
USA | $24.74 Trillion |
Liability Composition Analysis (2021–2025)
This chart breaks down GENMAB AS SP.ADR/1/10DK 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of GENMAB AS SP.ADR/1/10DK 1 to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENMAB AS SP.ADR/1/10DK 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
The table below shows the annual total liabilities of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.03 Billion ≈ $8.21 Billion |
+452.55% |
| 2024-12-31 | €1.27 Billion ≈ $1.49 Billion |
+132.79% |
| 2023-12-31 | €546.23 Million ≈ $638.60 Million |
+33.77% |
| 2022-12-31 | €408.32 Million ≈ $477.37 Million |
+10.33% |
| 2021-12-31 | €370.09 Million ≈ $432.67 Million |
-- |
About GENMAB AS SP.ADR/1/10DK 1
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more